 safety pharmacokinetics subjects AIDS AIDS-related complex phase phase study safety pharmacokinetics single intravenous infusion subjects AIDS AIDS-related complex ARC active ingredient trichosanthin Trichosanthin China active drug community-initiated treatment programs patients HIV infection Eighteen subjects AIDS ARC subjects tolerance toxicity Immunological virological parameters administration notable toxicity exception subject severe neurological adverse reaction consistent changes lymphocyte populations HIV antigen levels Serum concentrations comparable concentrations antiviral activity vitro sufficient duration antiretroviral effects Further studies pharmacodynamic properties optimal dosing schedule molecules useful treatment HIV infection